Clinical Trial Update: Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update examining pembrolizumab in combination with sunitinib malate for refractory metastatic or unresectable thymic carcinoma; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Sutent (sunitinib)

Snippet

Sponsor: Dwight Owen | Conditions: Thymic Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING